Daniel L. Flynn
2017
In 2017, Daniel L. Flynn earned a total compensation of $1.1M as Chief Scientific Officer at Deciphera Pharmaceuticals.
Compensation breakdown
| Non-Equity Incentive Plan | $124,000 |
|---|---|
| Option Awards | $611,441 |
| Salary | $343,750 |
| Other | $8,100 |
| Total | $1,087,291 |
Flynn received $611.4K in option awards, accounting for 56% of the total pay in 2017.
Flynn also received $124K in non-equity incentive plan, $343.8K in salary and $8.1K in other compensation.
Rankings
In 2017, Daniel L. Flynn's compensation ranked 8,590th out of 14,666 executives tracked by ExecPay. In other words, Flynn earned more than 41.4% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 8,590 out of 14,666 | 41st |
Division Manufacturing | 3,262 out of 5,768 | 43rd |
Major group Chemicals And Allied Products | 1,091 out of 2,074 | 47th |
Industry group Drugs | 864 out of 1,730 | 50th |
Industry Pharmaceutical Preparations | 675 out of 1,329 | 49th |
Source: SEC filing on April 3, 2018.
Flynn's colleagues
We found two more compensation records of executives who worked with Daniel L. Flynn at Deciphera Pharmaceuticals in 2017.